NCT00102804 · BASELINE

Baseline characteristics

Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC) · Source last updated 2014-12-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

counts
group Id
BG000
value
441
group Id
BG001
value
222
group Id
BG002
value
663
units
Participants

groups

description
Pemetrexed: 500 mg/m\^2, IV administration, q 21 days, until disease progression. BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
id
BG000
title
Pemetrexed and BSC
description
Placebo: IV administration, q 21 days. BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
id
BG001
title
Placebo and BSC
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
lower Limit
54.3
upper Limit
67.5
value
60.6
group Id
BG001
lower Limit
53.8
upper Limit
67.0
value
60.4
group Id
BG002
lower Limit
54.1
upper Limit
67.4
value
60.6
dispersion Type
INTER_QUARTILE_RANGE
param Type
MEDIAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
119
group Id
BG001
value
61
group Id
BG002
value
180
title
Female
measurements
group Id
BG000
value
322
group Id
BG001
value
161
group Id
BG002
value
483
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
1
title
Aboriginal
categories
measurements
group Id
BG000
value
6
group Id
BG001
value
0
group Id
BG002
value
6
title
African
categories
measurements
group Id
BG000
value
279
group Id
BG001
value
149
group Id
BG002
value
428
title
Caucasian
categories
measurements
group Id
BG000
value
104
group Id
BG001
value
50
group Id
BG002
value
154
title
East Asian
categories
measurements
group Id
BG000
value
13
group Id
BG001
value
6
group Id
BG002
value
19
title
Hispanic
categories
measurements
group Id
BG000
value
39
group Id
BG001
value
16
group Id
BG002
value
55
title
West Asian
param Type
NUMBER
title
Race/Ethnicity, Customized
unit Of Measure
participants
classes
categories
measurements
group Id
BG000
value
20
group Id
BG001
value
12
group Id
BG002
value
32
title
United States
categories
measurements
group Id
BG000
value
5
group Id
BG001
value
4
group Id
BG002
value
9
title
Taiwan
categories
measurements
group Id
BG000
value
18
group Id
BG001
value
9
group Id
BG002
value
27
title
Greece
categories
measurements
group Id
BG000
value
30
group Id
BG001
value
19
group Id
BG002
value
49
title
Spain
categories
measurements
group Id
BG000
value
7
group Id
BG001
value
4
group Id
BG002
value
11
title
Turkey
categories
measurements
group Id
BG000
value
2
group Id
BG001
value
2
group Id
BG002
value
4
title
Austria
categories
measurements
group Id
BG000
value
18
group Id
BG001
value
16
group Id
BG002
value
34
title
Italy
categories
measurements
group Id
BG000
value
39
group Id
BG001
value
16
group Id
BG002
value
55
title
India
categories
measurements
group Id
BG000
value
8
group Id
BG001
value
6
group Id
BG002
value
14
title
Hungary
categories
measurements
group Id
BG000
value
5
group Id
BG001
value
2
group Id
BG002
value
7
title
Czech Republic
categories
measurements
group Id
BG000
value
25
group Id
BG001
value
11
group Id
BG002
value
36
title
Poland
categories
measurements
group Id
BG000
value
24
group Id
BG001
value
10
group Id
BG002
value
34
title
Brazil
param Type
NUMBER
title
Region of Enrollment
unit Of Measure
participants

population Description

Participants who signed the ICF and completed the randomized process are reported according to the treatment arm to which they were randomized.

Complete source fields

denoms

counts
group Id
BG000
value
441
group Id
BG001
value
222
group Id
BG002
value
663
units
Participants

groups

description
Pemetrexed: 500 mg/m\^2, IV administration, q 21 days, until disease progression. BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
id
BG000
title
Pemetrexed and BSC
description
Placebo: IV administration, q 21 days. BSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
id
BG001
title
Placebo and BSC
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
lower Limit
54.3
upper Limit
67.5
value
60.6
group Id
BG001
lower Limit
53.8
upper Limit
67.0
value
60.4
group Id
BG002
lower Limit
54.1
upper Limit
67.4
value
60.6
dispersion Type
INTER_QUARTILE_RANGE
param Type
MEDIAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
119
group Id
BG001
value
61
group Id
BG002
value
180
title
Female
measurements
group Id
BG000
value
322
group Id
BG001
value
161
group Id
BG002
value
483
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
1
title
Aboriginal
categories
measurements
group Id
BG000
value
6
group Id
BG001
value
0
group Id
BG002
value
6
title
African
categories
measurements
group Id
BG000
value
279
group Id
BG001
value
149
group Id
BG002
value
428
title
Caucasian
categories
measurements
group Id
BG000
value
104
group Id
BG001
value
50
group Id
BG002
value
154
title
East Asian
categories
measurements
group Id
BG000
value
13
group Id
BG001
value
6
group Id
BG002
value
19
title
Hispanic
categories
measurements
group Id
BG000
value
39
group Id
BG001
value
16
group Id
BG002
value
55
title
West Asian
param Type
NUMBER
title
Race/Ethnicity, Customized
unit Of Measure
participants
classes
categories
measurements
group Id
BG000
value
20
group Id
BG001
value
12
group Id
BG002
value
32
title
United States
categories
measurements
group Id
BG000
value
5
group Id
BG001
value
4
group Id
BG002
value
9
title
Taiwan
categories
measurements
group Id
BG000
value
18
group Id
BG001
value
9
group Id
BG002
value
27
title
Greece
categories
measurements
group Id
BG000
value
30
group Id
BG001
value
19
group Id
BG002
value
49
title
Spain
categories
measurements
group Id
BG000
value
7
group Id
BG001
value
4
group Id
BG002
value
11
title
Turkey
categories
measurements
group Id
BG000
value
2
group Id
BG001
value
2
group Id
BG002
value
4
title
Austria
categories
measurements
group Id
BG000
value
18
group Id
BG001
value
16
group Id
BG002
value
34
title
Italy
categories
measurements
group Id
BG000
value
39
group Id
BG001
value
16
group Id
BG002
value
55
title
India
categories
measurements
group Id
BG000
value
8
group Id
BG001
value
6
group Id
BG002
value
14
title
Hungary
categories
measurements
group Id
BG000
value
5
group Id
BG001
value
2
group Id
BG002
value
7
title
Czech Republic
categories
measurements
group Id
BG000
value
25
group Id
BG001
value
11
group Id
BG002
value
36
title
Poland
categories
measurements
group Id
BG000
value
24
group Id
BG001
value
10
group Id
BG002
value
34
title
Brazil
param Type
NUMBER
title
Region of Enrollment
unit Of Measure
participants

population Description

Participants who signed the ICF and completed the randomized process are reported according to the treatment arm to which they were randomized.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice